Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Paragon BioTeck Reformulates Freshkote, Prompting Eyevance Acquisition

By Paragon BioTeck | September 18, 2018

Paragon BioTeck, a privately held pharmaceutical and medical device company specializing in the development and commercialization of ophthalmic pharmaceuticals, devices, and therapies, recently completed the reformulation for the Freshkote family of lubricant eye drops, purchased this week by Eyevance Pharmaceuticals.

“We are pleased to be able to have a role in the improvements made to the Freshkote products that make the product line an attractive acquisition for Eyevance,” said Patrick Witham, president and CEO of Paragon BioTeck. “Freshkote PF, which we formulated as a preservative-free product available in a multi-dose bottle and in single-unit vials, will be a welcome addition for physicians who have been seeking a preservative-free product to recommend to their patients.”

“It’s been a pleasure working with the Paragon team to make this acquisition a reality,” said Jerry St. Peter, CEO and director of Eyevance. “We look forward to marketing Freshkote PF to eye care practitioners nationwide.”

Committed to enhancing the quality of life of patients, Paragon BioTeck develops and commercializes eye health products. The company’s product portfolio includes branded over-the-counter and prescription solutions to diagnose, manage, and treat ocular conditions.

“Our scientists were particularly pleased to have the opportunity to develop a preservative-free formulation that is safe and well-tolerated by patients wearing contact lenses,” Witham added. “This project further demonstrates our mission to developing new and innovative products and technologies that advance ocular medicine.”

(Source: Paragon BioTeck)

Related Articles Read More >

Novartis logo
Novartis mulls sale of $25 billion Sandoz generics arm
Pfizer logo
Pfizer seeks to comply with voluntary Net-Zero Standard by 2040
Fujifilm Diosynth Technologies
Fujifilm to spend $1.6B to bolster cell culture manufacturing services
Zantac
First Zantac trial slated for February 2023

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards